Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (1186)	3/21/2002 7:07:24 AM
From: mopgcw	of 1298

Cell Genesys To Discontinue Gene Pact With GPC Biotech DOW JONES NEWSWIRES FOSTER CITY, Calif. -- Cell Genesys Inc. (CEGE) ended its research collaboration and license agreement for certain gene therapy with GPC Biotech AG (G.GPC) as part of its reprioritizing of preclinical programs in cancer gene therapy. In a press release Thursday, Cell Genesys said the move also reflects its determination that the p27/p16 gene therapy for cardiovascular disorders such as restenosis is "a less compelling opportunity" in light of the success of new treatments including drug-coated stents. Cell Genesys had been conducting preclinical research studies in the collaboration since 1998. The agreement began when the company licensed a family of cell cycle inhibitor genes from Mitotix Inc., which GPC acquired in 2002. Cell Genesys said it plans to give a higher priority to its other programs, including oncolytic viruses and antiangiogenesis gene therapy, based on the strength of preclinical data for those product candidates. On Sunday, results from a study on a drug-coated stent developed by Johnson & Johnson (JNJ) to prop open blocked arteries showed that the wire mesh tubes, coated with the antibiotic Sirolimus, remain effective at preventing restenosis without causing major medical complications. Restenosis occurs when blockage forms in a blood vessel after doctors have performed surgery to remove an obstruction. In about 20% to 35% of patients who undergo an angioplasty to remove a blockage from a coronary blood vessel, scar tissue develops and reblocks the vessel. Guidant Corp. (GDT), Boston Scientific Corp. (BSX) and Abbott Laboratories (ABT) also are developing drug-coated stents. Cell Genesys Web site: cellgenesys.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next